AstraZeneca: selumetinib gets orphan status in Europe
(CercleFinance.com) - AstraZeneca's experimental drug, selumetinib, has received orphan drug status from the European Medicines Agency (EMA) for the treatment of neurofibromatosis type 1 (NF1), a rare condition, the company said on Friday.
NF1 affects approximately one in 3,000 people at birth and is associated with many symptoms, including soft lumps, skin pigmentation, and benign tumours on nerve sheaths.
There is currently no cure for the disease, AstraZeneca said.
Selumetinib has been licensed by AstraZeneca from Array BioPharma since 2003. In 2017, the drugmaker and its US partner entered into an agreement for the joint-development of the drug.
Copyright (c) 2018 CercleFinance.com. All rights reserved.
NF1 affects approximately one in 3,000 people at birth and is associated with many symptoms, including soft lumps, skin pigmentation, and benign tumours on nerve sheaths.
There is currently no cure for the disease, AstraZeneca said.
Selumetinib has been licensed by AstraZeneca from Array BioPharma since 2003. In 2017, the drugmaker and its US partner entered into an agreement for the joint-development of the drug.
Copyright (c) 2018 CercleFinance.com. All rights reserved.